Newspaper article Pittsburgh Post-Gazette (Pittsburgh, PA)

Top Mylan Exec Named in Expanded Federal Price-Fixing Lawsuit

Newspaper article Pittsburgh Post-Gazette (Pittsburgh, PA)

Top Mylan Exec Named in Expanded Federal Price-Fixing Lawsuit

Article excerpt

Mylan president Rajiv Malik has been named in an expanded federal lawsuit filed by attorneys general in nearly every state, including Pennsylvania, that accuses Mylan and more than a dozen other drugmakers of conspiring to fix prices for generic drugs.

The amended complaint, which state officials are asking federal court for permission to file, also names Satish Mehta, CEO of the India-based drugmaker Emcure Pharmaceuticals, the parent company of Heritage Pharmaceuticals in New Jersey.

Mr. Malik and Mr. Mehta would be the first senior executives sued in the case.

"These conspiracies were part of a much broader, overarching industry code of conduct that enabled the [drugmakers] to divvy up the market for specific generic drugs in accordance with an established, agreed-upon understanding for assigning each competitor their share of the market," said Connecticut Attorney General George Jepsen, who is leading the antitrust investigation, in a statement.

The original lawsuit, filed in December 2016 in Connecticut and moved to Philadelphia in August, named Mylan, Heritage Pharmaceuticals and four other drugmakers, accusing them of conspiring to fix prices for two drugs. The new complaint expands the number of generic drug companies to 18 and the number of drugs at issue to 15.

The U.S. Department of Justice also is conducting a probe.

"Mylan has deep faith in the integrity of its president, Rajiv Malik, and stands behind him fully," Mylan, which is run from executive offices in Cecil, said in a statement Tuesday.

"We have been investigating these allegations thoroughly and have found no evidence of price fixing on the part of Mylan or its employees," the company said, adding that it would "defend this case vigorously."

The complaint alleges that the misconduct was conceived and carried out by senior drug company executives and their subordinate marketing and sales executives.

The lawsuit also contends that the companies knew their conduct was illegal and made efforts to avoid communicating with each other in writing, or in some instances, to delete written electronic communications after becoming aware of the investigation. …

Search by... Author
Show... All Results Primary Sources Peer-reviewed

Oops!

An unknown error has occurred. Please click the button below to reload the page. If the problem persists, please try again in a little while.